1. Home
  2. ABCL vs XNCR Comparison

ABCL vs XNCR Comparison

Compare ABCL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABCL
  • XNCR
  • Stock Information
  • Founded
  • ABCL 2012
  • XNCR 1997
  • Country
  • ABCL Canada
  • XNCR United States
  • Employees
  • ABCL N/A
  • XNCR N/A
  • Industry
  • ABCL Biotechnology: Pharmaceutical Preparations
  • XNCR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ABCL Health Care
  • XNCR Health Care
  • Exchange
  • ABCL Nasdaq
  • XNCR Nasdaq
  • Market Cap
  • ABCL 1.1B
  • XNCR 1.1B
  • IPO Year
  • ABCL 2020
  • XNCR 2013
  • Fundamental
  • Price
  • ABCL $3.61
  • XNCR $17.71
  • Analyst Decision
  • ABCL Buy
  • XNCR Buy
  • Analyst Count
  • ABCL 5
  • XNCR 11
  • Target Price
  • ABCL $7.75
  • XNCR $23.20
  • AVG Volume (30 Days)
  • ABCL 5.2M
  • XNCR 898.0K
  • Earning Date
  • ABCL 11-06-2025
  • XNCR 11-05-2025
  • Dividend Yield
  • ABCL N/A
  • XNCR N/A
  • EPS Growth
  • ABCL N/A
  • XNCR N/A
  • EPS
  • ABCL N/A
  • XNCR N/A
  • Revenue
  • ABCL $35,325,000.00
  • XNCR $150,132,000.00
  • Revenue This Year
  • ABCL $16.99
  • XNCR $22.09
  • Revenue Next Year
  • ABCL $62.91
  • XNCR N/A
  • P/E Ratio
  • ABCL N/A
  • XNCR N/A
  • Revenue Growth
  • ABCL 7.17
  • XNCR 38.16
  • 52 Week Low
  • ABCL $1.89
  • XNCR $6.92
  • 52 Week High
  • ABCL $6.52
  • XNCR $27.24
  • Technical
  • Relative Strength Index (RSI)
  • ABCL 33.35
  • XNCR 71.33
  • Support Level
  • ABCL $3.33
  • XNCR $15.38
  • Resistance Level
  • ABCL $3.83
  • XNCR $16.63
  • Average True Range (ATR)
  • ABCL 0.27
  • XNCR 0.95
  • MACD
  • ABCL -0.01
  • XNCR 0.21
  • Stochastic Oscillator
  • ABCL 34.30
  • XNCR 98.50

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Share on Social Networks: